suPAR is a potential biomarker for triage of patients with COVID-19 symptoms in the ED

Tue Mar 30 2021

Soluble urokinase plasminogen activator receptor as a decision marker for early discharge of patients with COVID-19 symptoms in the emergency department

published in The Journal of Emergency Medicine

A newly published paper written ED doctors shows that suPAR is a potential biomarker for triage and safe early discharge of patients with COVID-19 symptoms in the ED. suPAR can even be used even before SARS-CoV-2 status is known.

SARS-CoV-2 strains healthcare capacity. Better risk stratification, with discharge of patients with a predicted mild disease trajectory, can ease this burden. Elevated suPAR has previously been shown associated with risk of intubation in confirmed COVID-19 patients.

386 patients were included strengthening the paper’s COVID-19 conclusions, as well as the notion that suPAR is a biomarker that can help ED physicians decide whether a patient should be admitted or, in fact, can safely be discharged.

This helps reducing crowding in the ED and may thus allow overburdened COVID-19 staff across our hospitals to get a five-min break during their current COVID-19 24/7 schedules.

suPAR is a potential biomarker for triage and safe early discharge of patients with COVID-19 symptoms in the ED.

– Stauning et al, Journal of Emergency Medicine, March 2021

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

suPARnostic POC+

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates